Genentech says SAkuraSky data published in New England Journal of Medicine
Genentech, a member of the Roche Group, announced that data from SAkuraSky, a pivotal Phase III study of the investigational medicine satralizumab for the treatment of neuromyelitis optica spectrum disorder, or NMOSD, were published in the November 27, 2019 online issue of the New England Journal of Medicine, or NEJM. "The positive results from the pivotal SAkuraSky study of satralizumab support the hypothesis that IL-6 plays a key role in NMOSD, which is a debilitating and potentially fatal condition," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "Satralizumab has shown robust efficacy sustained for 144 weeks across a broad patient population in two Phase III studies, whether given as a monotherapy or in combination with baseline therapy. We're encouraged that satralizumab may soon provide a new treatment option for people living with NMOSD."